Objective: Obese patients with schizophrenia being treated with clozapine and non-psychiatric obese are often assumed to share the same physiological changes in obesity. The aim of this study was to identify possible metabolic and hormonal differences between non-psychiatric obese subjects (OB) and obese patients with schizophrenia being treated with clozapine (OSC). Subjects: Fifty-one normal healthy subjects (Nor, body mass index (BMI):23.270.3), 50 OB (BMI:31.770.7) and 71 OSC (BMI:30.470.5). Measurements: Anthropometric, metabolic and hormonal parameters were determined by anthropometry, enzyme autoanalyzer, immunoassay and enzyme-linked immunosorbent assay. Results: Triglyceride, total cholesterol divided by high-density lipoprotein (HDL) cholesterol (TC/HDL) and leptin levels were significantly higher whereas the HDL and the molar ratio of insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein (IGFBP)-3 levels were significantly lower in both OB and OSC groups than those in the Nor group. Compared to normal subjects, insulin and homeostasis model assessment (HOMA) index levels were significantly higher in OSC, and, in OSC, insulin sensitivity and insulin-like growth factor (IGF)-1 were significantly lower. Although the anthropometric parameters in the OB and OSC groups were similar, in the OSC group the waist-to-hip ratio (WHR), insulin levels and HOMA index were significantly higher, while insulin sensitivity, cholesterol, low-density lipoprotein (LDL) cholesterol, TC/HDL, LDL/HDL, IGF-1 and IGF-1/IGFBP-3 molar ratio were lower, than those of the OB group. Conclusion: Insulin homeostasis and lipid profiles in clozapine-treated schizophrenic obesity were different from those in nonpsychiatric obesity with similar anthropometric parameters, body weight and BMI. Among the three groups, the highest fasting insulin, the lowest insulin sensitivity and the highest HOMA index occurred in the OSC group. The OSC group was characterized by impaired glucose-insulin homeostasis, abnormal lipid profiles and hormonal changes in the GH-IGF-IGFBP axis and in leptin.
Introduction
Patients with schizophrenia treated with atypical antipsychotic drugs, such as clozapine, often experience significant weight gain and become obese. 1 Clozapine has been documented with superior efficacy for treatment of patients with refractory schizophrenia, 2 but clozapine is associated with serious safety liabilities 3 in addition to weight gain, including metabolic abnormalities and increased prevalence of type 2 diabetes mellitus and cardiovascular diseases. 4, 5 Bunce et al. 6 reported that 50% of 2395 psychiatric outpatients and 52% of 1448 psychiatric in-patients had major medical disorders, but many of these illnesses are misdiagnosed or undiagnosed. 7 It is important to investigate metabolic or hormonal abnormalities in patients with schizophrenia who take atypical antipsychotic drugs, especially clozapine. The increased prevalence of type 2 diabetes and abnormalities in glucose regulation in schizophrenia after clozapine treatment have been reported. [8] [9] [10] [11] However, levels of insulin and insulin sensitivity in schizophrenia treated with clozapine appear to be controversial: two studies report higher insulin levels and blunted insulin sensitivity 12, 13 while another reports no changes in insulin levels and insulin resistance. 14 Significant elevations in triglyceride levels have also been reported in association with clozapine treatment. 9, 11, 15, 16 Slight decrease in high-density lipoprotein (HDL) and no change in low-density lipoprotein (LDL) levels in schizophrenic patients after clozapine treatment has been shown in one study 9 whereas two other studies demonstrate less change in HDL or LDL. 11, 16 Although many studies report metabolic and hormonal changes in schizophrenia after clozapine treatment, until now it has not been investigated whether clozapine-treated schizophrenic obesity shows metabolic and hormonal changes that differ from those of non-psychiatric and non-clozapine-treated obesity when anthropometric parameters remain similar. Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are powerful regulatory agents for maintaining cardiovascular function. 17, 18 In humans, IGF-1 appears to improve cardiovascular function, whereas low IGF-1 levels are associated with increased risk for heart disease. 18, 19 Insulin-like growth factor binding protein-3 (IGFBP-3) is the most abundant binding protein, carrying most of the circulating IGFs (90% in adult serum). IGFBP-3 controls the actions of the IGFs by regulating their distribution and bioavailability to target tissues. 20 The IGF-IGFBP-3 axis is involved in the pathogenesis of cardiovascular dysfunction, [17] [18] [19] ischemic stroke 21 and atherosclerosis. 22 Individuals with low circulating IGF-1 levels and high IGFBP-3 levels have been reported to have significantly increased risk of developing ischemic heart disease during a 15-year followup period. 23 Although a previous study demonstrated a lower median level of IGF-1 and lower GH secretion in schizophrenic patients receiving clozapine, 24 until now the characteristics of the IGF-IGFBP-3 axis in schizophrenic obesity versus non-psychiatric obesity have remained unclear. The metabolic and hormonal differences between nonpsychiatric obese subjects (OB) and obese patients with schizophrenia treated with clozapine (OSC) are, before this publication, still unknown. This study had two aims: to investigate the anthropometric, metabolic and hormonal parameters in normal healthy subjects (Nor), OB and OSC, and to identify possible metabolic and hormonal differences in OB and OSC.
Materials and methods
Subjects Seventy-one hospitalized obese patients (body mass index (BMI) X27) diagnosed with DSM-IV schizophrenia who treated with clozapine were recruited from the Yu-Li Veterans' hospital in eastern Taiwan and were regarded as OSC group. Age-matched 50 non-psychiatric obese subjects (BMI X27) and fifty-one normal-weight (18.5pBMIp24 kg m
À2
) healthy subjects were recruited from residents living in Yu-Li community including hospital staff and were regarded as OB group and Nor group, respectively. All subjects included in the study were between the ages of 17 and 66 years. The dose and treatment duration of clozapine in the OSC group was from 100 to 600 mg per day and from 0.5 to 10.92 years. All subjects were excluded for organ failure, lipid-lowering medications, pregnancy or lactation; for being in the acute phase of mental illness; or for being unable to provide informed consent from exacerbation of psychiatric symptoms or from cognitive decline, as judged by the psychiatrist in charge. The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Review Committee of Yu-Li Veterans Hospital. The study was completely described to all subjects, who provided written informed consent before participating.
Anthropometric measurements
The assessments of anthropometric parameters and body composition were performed after an overnight fasting. Body weight and body-fat percentage (fat %) were measured by a body composition analyzer with bioelectrical impedance analysis (TBF-410, TANITA, Japan). Height was measured by a calibrated stadiometer. Waist and hip circumferences were measured in a standing position at the end of gentle expiration by calibrated plastic tapes at mid-way between the lowest rib and the iliac crest and at the greater trochanters, respectively. Waist and hip circumferences were expressed in centimeters (cm). BMI was calculated as weight divided by height squared (kg m
À2
). The waist-to-hip ratio (WHR) was calculated as waist circumference divided by hip circumference.
Blood sampling
Overnight fasting blood samples were drawn from patients between 0700 and 0900 hours by a trained phlebotomist with venipuncture of an antecubital vein. Part of each blood sample was immediately used for the metabolic analysis and enzyme assay, while the other part of the sample was centrifuged at 3000 r.p.m. for 15 mins at 4 1C within 1 h of drawing and subsequently frozen at À80 1C until an enzymelinked immunosorbent assay analysis could be performed.
Metabolic analysis and enzyme immunoassay
Serum glucose, insulin, cortisol, triglyceride, cholesterol, HDL-C, LDL-C, leptin were immediately measured from freshly drawn blood samples. Serum glucose, triglycerides, total cholesterol, HDL-C and LDL-C were measured by a glucose-oxidase autoanalyzer, a triglyceride-enzyme autoanalyzer and a cholesterol-oxidase autoanalyzer (Dimension RxL, DADE Behring Inc., Newark, DE, USA), respectively.
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Serum cortisol and insulin were measured by an enzymeimmunoassay system (ACCESS, Backman, Minneapolis, Minn, USA). The homeostasis model assessment (HOMA) index was calculated as fasting insulin concentration (mU ml À1 ) Â fasting glucose concentration (mM)/22.5. Insulin sensitivity is equal to 22.5 divided by fasting insulin concentration (mU ml
À1
) Â fasting glucose concentration (mM).
Enzyme-linked immunosorbent assay measurements
Leptin, GH, IGF-1 and IGFBP-3 levels were determined by commercially available enzyme-linked immunosorbent assay kits (Diagnostic Systems Laboratories Inc, Webster, TX, USA) with the VERSA max tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA). Those assays are non-competitive and involve horseradish peroxidase-labeled detection antibody, as described previously. 25 
Statistical analysis
All parameters in all three groups (Nor, OB and OSC) were analyzed by analysis of variance using the general-linear model (GLM) in a one-way analysis of variance with post-hoc comparison. In all cases, a difference of Po0.05 was considered statistically significant and 95% confidence intervals were calculated. All data presented in text and tables are means7s.e.m.
Results
The mean age and height in the Nor, OB and OSC groups were similar ( Table 1 ). The mean dose of clozapine was 303.5712.5 mg per day, and the mean duration of clozapine treatment was 3.9970.34 years in the OSC group. The mean body weight, BMI, waist girth, hip girth, WHR, fat percentage of body weight (%) and fat mass in the OB and OSC groups were significantly (Po0.01) higher than those in the Nor group. The WHR levels in the OSC group were significantly higher than those in the OB group (Table 1) .
Triglyceride, total cholesterol divided by HDL (TC/HDL) and leptin levels were significantly higher whereas the HDL level was significantly lower in both OB and OSC groups than those in the Nor group (Table 2) . Glucose, cholesterol, LDL-C and LDL/HDL levels were significantly higher in the OB group only and not in the OSC group (Table 2) whereas insulin, HOMA index levels were significantly higher and insulin sensitivity was significantly lower in the OSC group, but not in the OB group, compared with Nor. Compared with OB, insulin and HOMA index levels in the OSC group were significantly higher, whereas insulin sensitivity, cholesterol, LDL-C, TC/HDL and LDL/HDL levels were significantly lower (Table 2 ). No difference in cortisol level was found among the three groups (Table 2) .
Insulin-like growth factor-1 (IGF-1) was significantly (Po0.01) lower only in the OSC group, but not in the OB group (Table 3) , compared with Nor. The molar ratio of IGF-1 and IGFBP-3 levels were significantly lower in both obese groups, compared with the Nor group (Table 3) . Compared with OB, both IGF-1 and IGF-1/IGFBP-3 levels in the OSC group were significantly lower. No significant differences were found in GH or in IGFBP-3 levels among the three groups (Table 3) .
Discussion
Non-psychiatric obese patients and schizophrenic obese patients have often been assumed to have identical physiological changes owing to obesity. In this study, although obese subjects in these two groups indeed shared similar Schizophrenic obesity M-K Wu et al anthropometric and lipid-profile characteristics, with the exceptions of WHR, cholesterol, LDL-C and LDL/HDL, other metabolic and hormonal parameters in OSC group differed from those in the non-psychiatric obesity. Among the three groups, the highest fasting insulin, the lowest insulin sensitivity and the highest HOMA index were found in the OSC group. In addition, our study demonstrates that the clozapine-treated schizophrenic obesity was characterized by hyperinsulinemia, insulin resistance and hormonal changes in the GH-IGF-IGFBP axis, whereas these parameters in OB group (excepting the molar ratio of IGF-1/IGFBP-3) was similar to those of Nor group. Patients with schizophrenia being treated with clozapine often manifest a marked increase in central adiposity. [26] [27] [28] It has been shown, however, that WHR is actually a better predictor of cardiovascular disease and death than any actual amount of adiposity. A WHR value of 0.85 for woman and 1.0 for men has been proposed as the cutoff for central obesity, with a concomitant high risk for cardiovascular disease. 29 In our study, the average WHR in our female obese patients (both psychiatric and non-psychiatric obese) was 0.89 and 0.86, respectively, and therefore qualified as central obesity with higher cardiovascular risk factors. Our male obese subjects, with an average WHR of 0.97 in schizophrenic obesity and 0.93 in non-psychiatric obesity, do not qualify as centrally obese. In this study, the normal blood glucose levels, instead of hypoglycemia, in the patients receiving clozapine may support the theory that clozapine induces peripheral insulin resistance and secondary increased insulin secretion, even though a direct stimulatory effect of clozapine on the pancreatic b cells cannot be excluded. 24 The HOMA index is one of the most widely used indices of insulin resistance, defined as a decrease of sensitivity of body tissues to serum insulin. Fasting hyperinsulinemia, insulin resistance and the HOMA index not only partially predict type 2 diabetes in Table 3 The hormonal characteristics of normal healthy subjects, non-psychiatric obese subjects and obese patients with schizophrenia being treated with clozapine Schizophrenic obesity M-K Wu et al various populations, but also are important risk factors for coronary artery disease or cardiovascular events. Furthermore, the OSC group had plasma insulin and HOMA index levels that were significantly higher than those of the nonpsychiatric obese subjects, which may suggest further metabolic deterioration in the psychiatric patients. Epidemiologic data suggest that diabetes in patients with schizophrenia is more prevalent (about 1.5-2.0 times 30 ) than in the general population, and that these patients have greater risk (about 3-fold 31 ) than does the general population of developing the metabolic syndrome. Schizophrenia is associated not only with abnormalities in glucose-insulin homeostasis that may lead to insulin resistance, but also with a 2-to 3-fold higher incidence of type 2 diabetes mellitus. [32] [33] Abnormalities in peripheral glucose regulation and type 2 diabetes mellitus co-existing with increased insulin occur more commonly in individuals with schizophrenia compared with in the general population. 34 Moreover, in general, insulin concentrations are significantly positively associated with BMI and WHR. 35 We have already noted that the OSC group had the highest fasting insulin and HOMA index and the lowest insulin sensitivity of all the three groups. 36 and demonstrate that obese patients with schizophrenia treated with clozapine suffer from a greater lack of glucose-insulin homeostasis than do either the general population or people with obesity who have similar anthropometric characteristics. In the present study, triglyceride levels were much higher in both of our obese groups compared with the normal group. Elevated triglyceride concentrations have also previously been observed in patients treated with clozapine, whether obese or non-obese. 9, 11, [15] [16] 26 Total cholesterol, LDL-cholesterol and LDL/HDL in our OSC group were not significantly different from those measures in normal subjects. On the other hand, our data show that the OB group had significantly higher glucose, triglyceride, cholesterol, LDL-C, TC/HDL ratio, LDL/HDL and leptin than did controls, suggesting markedly increased abnormalities of lipid profiles in the OB group. Clozapine appears to have a remarkable influence on triglyceride levels but only minor influence in other lipid measures such as total, LDL-and HDL-cholesterol. Leptin is a hormone produced by adipocytes that correlates in quantity with both BMI and percent of body fat. Leptin secretion is presumed to signal the size of the adipose depot to brain and peripheral tissues. In the current study, hyperleptinemia was observed in both of our obese groups.
Growth hormone and IGF-1 are known to be powerful regulators of cardiovascular function. 17, 18 Conversely, low levels of GH or IGF-1 are associated with increased risk for impaired glucose tolerance, type 2 diabetes or cardiovascular disease 37 because a low level of IGF-1 in itself is accompanied by insulin resistance and increased insulin secretion. 38 In the present study, serum IGF-1 levels were markedly decreased in the OSC group and decreased, but not significantly, in the OB group, compared with normal subjects. Because of the lower levels of IGF-1 and equivalencies in levels of IGFBP-3, both of the obese groups had a lower IGF-1/IGFBP-3 molar ratio. The ratio between IGF-1 and IGFBP-3 is considered a marker of active IGF-1, which determines the equilibrium between total and bound IGF-1. 24 These findings imply that 'active IGF-1' was reduced in both non-psychiatric obese subjects and obese patients with schizophrenia being treated with clozapine. These findings strongly suggest that greater alterations in the GH-IGF axis and more IGF dysfunction occur in obese patients with schizophrenia being treated with clozapine than in non-psychiatric obese subjects. Consistent with our findings, lower GH secretion and lower median levels of IGF-1 were also found in 13 patients with BMIs of 2673 kg m À2 treated with clozapine. 24 However, Howes et al. 39 reported that clozapine does not alter GH and IGF-1 secretion within 3 months of its administration. The disparity in our results and those of Howes et al. 39 may potentially be related to differences in dosage, therapeutic duration, sample size or racial groups studied.
There are some limitations in the current study. All selected obese patients with schizophrenia being treated with clozapine are in-patients in a veterans' hospital in eastern Taiwan and non-obese patients with BMIo27 were all excluded in the current study. Therefore, in the current experimental design, we have to add a note of caution that any changes of glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis noted in OB or OSC group cannot be isolated to one specific factor, such as clozapine only, but may be affected directly or indirectly by various confounding factors, such as previous medication history, concomitant medication, exercise status, nutrition condition, hospital food or any neurotransmitter derangement underlying the patients' mental illnesses. However, this is the first crosssectional study of obese patients with schizophrenia being treated with clozapine to measure anthropometric parameters, glucose homeostasis, lipid profiles and GH-IGF-IGFBP axis parameters.
In conclusion, our study demonstrated that obese, schizophrenic patients treated with clozapine tend strongly toward hyperinsulinemia, insulin resistance, hypertriglycerides and hormonal changes in the GH-IGF-IGFBP axis and leptin levels. These changes suggest that abnormal glucose-insulin homeostasis, hypertriglycerides and GH-IGF-IGFBP axis may play a pathophysiologic role in development of diabetes or cardiovascular diseases. Schizophrenic patients are a population with increased metabolic and cardiovascular risks, major precipitating factors for their increased mortality. In addition, our results suggest that clinical assessments of these patients' health, including anthropometry and metabolic parameters (glucose, triglyceride, cholesterol and insulin), be performed on a regular basis. These clinical criteria may suggest a practical method for assessing over the 
